688163 Stock Overview
Engages in the research, development, production, operation, and sale of antitoxin and antiserum products in China.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Shanghai Serum Bio-Technology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥15.90 |
| 52 Week High | CN¥21.84 |
| 52 Week Low | CN¥10.98 |
| Beta | 0.36 |
| 11 Month Change | 21.00% |
| 3 Month Change | 31.51% |
| 1 Year Change | -18.71% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -71.25% |
Recent News & Updates
Shareholder Returns
| 688163 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 4.7% | -3.1% | -2.4% |
| 1Y | -18.7% | -23.9% | -20.1% |
Return vs Industry: 688163 exceeded the CN Biotechs industry which returned -23.9% over the past year.
Return vs Market: 688163 exceeded the CN Market which returned -20.1% over the past year.
Price Volatility
| 688163 volatility | |
|---|---|
| 688163 Average Weekly Movement | 6.5% |
| Biotechs Industry Average Movement | 5.9% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in CN Market | 8.7% |
| 10% least volatile stocks in CN Market | 3.7% |
Stable Share Price: 688163's share price has been volatile over the past 3 months.
Volatility Over Time: 688163's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 321 | Tiejiong Fan | www.serum-china.com.cn |
Shanghai Serum Bio-Technology Co., Ltd. engages in the research, development, production, operation, and sale of antitoxin and antiserum products in China. It offers equine anti-tetanus immunoglobulin, anti-venin, and anti-rabies serum products. The company was founded in 1999 and is based in Shanghai, China.
Shanghai Serum Bio-Technology Co., Ltd. Fundamentals Summary
| 688163 fundamental statistics | |
|---|---|
| Market cap | CN¥1.72b |
| Earnings (TTM) | CN¥44.17m |
| Revenue (TTM) | CN¥194.44m |
39.0x
P/E Ratio8.8x
P/S RatioIs 688163 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688163 income statement (TTM) | |
|---|---|
| Revenue | CN¥194.44m |
| Cost of Revenue | CN¥47.29m |
| Gross Profit | CN¥147.16m |
| Other Expenses | CN¥102.98m |
| Earnings | CN¥44.17m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.41 |
| Gross Margin | 75.68% |
| Net Profit Margin | 22.72% |
| Debt/Equity Ratio | 0.07% |
How did 688163 perform over the long term?
See historical performance and comparison